Under the terms of the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialise zaltenibart in all indications. Omeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net sales.
Zaltenibart is an antibody designed to inhibit MASP-3, a protein that acts as a key activator of the complement system’s alternative pathway. Dysregulation of the complement system, a crucial part of the immune system, has been shown to be involved in the pathophysiology of a number of rare diseases.
“Zaltenibart has a novel mode of action that could offer several advantages over other treatments for complement-mediated diseases,” said Martin Holst Lange, chief scientific officer and executive vice president of Research & Development at Novo Nordisk. “Novo Nordisk is in a strong position to build on the work done by Omeros to maximise the value of this asset and develop zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders.”
Omeros has reported positive phase 2 data for zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) - a rare, acquired blood disorder where the body's immune system mistakenly attacks and destroys red blood cells, leading to low levels of healthy red blood cells and other complications. Zaltenibart has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market, and it has been well tolerated and demonstrated an acceptable safety profile across all clinical trials to date.
“We are pleased to enter into this agreement with Novo Nordisk, a global leader in therapeutic innovation and development,” said Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros. “We look forward to Novo Nordisk levering its extensive expertise and global reach to unlock the potential of zaltenibart across alternative pathway indications. With Novo Nordisk driving the success of zaltenibart, Omeros remains focused on securing approval and commercialisation of narsoplimab this quarter and continuing to advance its robust development pipeline.”
Omeros retains certain rights to its preclinical MASP-3 programmes unrelated to zaltenibart, including the ability to develop and commercialise small-molecule MASP-3 inhibitors with limited indication restrictions.
Following closing of the transaction, Novo Nordisk aims to initiate a global phase 3 programme for zaltenibart in PNH and explore further development in a range of other rare blood and kidney disorders.
“With zaltenibart, we have a compelling opportunity to help a significant number of people living with rare blood and kidney disorders in the future and support our leadership ambition in this space,” said Ludovic Helfgott, executive vice president of Product and Portfolio Strategy at Novo Nordisk. “This agreement will build on Novo Nordisk’s heritage and enhance our existing Rare Disease portfolio with potential to drive additional growth in this business area.”
The transaction is subject to certain customary closing conditions, including applicable regulatory approvals, and is expected to close in the fourth quarter of 2025.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.